Minerva Neurosciences | NERV - Pre Utilidad Fiscal





Pre Utilidad Fiscal Cambio Fecha
Acadia Pharmaceuticals USD 3.98M 22.34M 2026-03
Adma Biologics USD 61.59M 14.07M 2025-12
ALKERMES USD -61.93M 122.3M 2026-03
Alterity Therapeutics Limited AUD -4.74M 3.53M 2024-12
AstraZeneca USD 3.91B 1.28B 2026-03
BioCryst Pharmaceuticals USD 248.02M 235.89M 2025-12
Bristol-Myers Squibb USD 1.47B 1.64B 2025-12
Cipla INR 7.49B 4.2B 2026-03
Clal Biotechnology ILS 86.82M 17.9M 2022-12
Compugen USD 56.84M 63.78M 2025-12
CSL USD 2.61B 1.21B 2025-12
Eli Lilly USD 8.27B 1.03B 2025-12
Esperion Therapeutics USD 63.67M 95M 2025-12
GlaxoSmithKline GBP 2.14B 919M 2026-03
Grifols EUR 257.85M 190.87M 2024-12
Halozyme Therapeutics USD 180.33M 281.18M 2026-03
Ionis Pharmaceuticals USD -93M 135M 2026-03
J&J USD 7.82B 2.86B 2026-03
Merck USD 3.42B 3.32B 2025-12
Minerva Neurosciences USD 22.51M 30.74M 2024-09
Neurocrine Biosciences USD 246.8M 7.4M 2026-03
Novartis USD 3.84B 802M 2026-03
Novavax USD 17.9M 220.94M 2025-12
Pfizer USD 5.18B 6.82B 2026-03
Roche Holding CHF 4.79B 3.01B 2025-06
Sanofi EUR -1.16B 5.5B 2025-12
Takeda JPY -52.48B 186.34B 2026-03
Vanda Pharmaceuticals USD -22.92M 16.68M 2024-12